Clinical trial of potential vaccine for coeliac disease
22 Mar 2018
USC’s Clinical Trials Centre will launch a clinical trial of a new vaccine on 23 March that aims to improve the lives of those with coeliac disease by ‘switching off’ the immune response to gluten.
Coeliac disease is a serious chronic medical condition in which the ingestion of gluten, even in small amounts, leads to an immune response that causes damage to the small intestine.
Sufferers struggle with various gastrointestinal symptoms and, if untreated, face potentially serious complications. Currently, the only way to manage the disease is by the strict avoidance of gluten in the diet.
He said the trial would be conducted alongside gastroenterologist Dr James Daveson at the Clinical Trial Centre on Sippy Downs Drive, Sippy Downs.
Dr Daveson said a gluten-free diet was exceptionally demanding for patients, expensive and difficult to maintain as gluten was used extensively in modern food production.
“There is a real unmet need for therapies other than the gluten-free diet for some people with coeliac disease,” he said. “This is a very exciting potential new therapy that has been undergoing clinical trials for several years now.”
Dr Daveson said the investigational vaccine might potentially restore gluten tolerance in coeliac disease sufferers.
Adults between the ages of 18 and 70 can take part in this trial if they have medically diagnosed coeliac disease and have been following a strict gluten-free diet for 12 months or more.
Those who meet the criteria and are enrolled in the study will be compensated for their time. Patients interested in participating can go to www.joinourtrials.com or phone (07) 5456 3797.
- Janelle Kirkland
Clinical trial of experimental new treatment for chronic plaque psoriasis28 Jan
USC Clinical Trials is about to begin a study of an experimental new treatment for mild to moderate chronic plaque psoriasis, a common skin condition.
USC Clinical Trials seeks healthy volunteers for malaria study5 Jan
USC Clinical Trials has partnered with the QIMR Berghofer Medical Research Institute in Brisbane to investigate whether an approved anti-malarial drug can be used more extensively to counter malaria – a disease that claims more than 400,000 lives worldwide each year.